BCG022 is a novel and fully human bispecific antibody-drug conjugate generated from the RenLite® platform that exhibits cross-species reactivity to human and cynomolgus monkey HER3 and MET.

BCG022 candidates can bind a wide range of HER3/MET co-expressing cancer cell lines, including NSCLC, gastric, liver, colorectal and pancreatic cancers.

BCG022 demonstrated higher endocytosis in HER3/MET co-expressing tumor cells than parental HER3 monoclonal ADCs, and stronger tumor growth inhibition than parental ADCs.

BCG022 showed strong anti-tumor efficacy in both CDX and PDX models.